Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammagard Liquid for primary versus secondary infection prophylaxis in adults with multiple myeloma receiving teclistamab
NL-OMON59625Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Feb 2026
- Countries
- 1
01
Overview
Phase 3, open-label trial of polyvalent human immunoglobulin in secondary immunodeficiency (SID) (2 arms), sponsored by Takeda. Primary endpoint: Time to first serious infection. Started Feb 2026; status: recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
secondary immunodeficiency (SID)
Beyond the preview
Go deeper on NL-OMON59625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59625.